ENDRA Life Sciences Inc. NDRA

Company Overview

ENDRA Life Sciences Inc. is a U.S.-based medical technology company focused on the development of advanced ultrasound imaging technologies designed to improve the detection and management of metabolic and liver-related diseases. The company operates within the medical device, diagnostic imaging, and digital health industries, with a primary emphasis on non-invasive imaging solutions for assessing tissue composition and liver health. ENDRA’s core technology platform is Thermo Acoustic Enhanced UltraSound (TAEUS®), which is designed to enhance conventional ultrasound by enabling clinicians to visualize and measure tissue characteristics that are difficult to detect using standard ultrasound alone.

The company’s principal commercial objective has centered on the use of TAEUS® for the assessment of fatty liver disease, including non-alcoholic fatty liver disease (NAFLD) and metabolic dysfunction-associated steatotic liver disease (MASLD). ENDRA positions its technology as a lower-cost, more accessible alternative to MRI-based liver fat quantification systems. Founded in 2007 and headquartered in Ann Arbor, Michigan, the company evolved from an early-stage imaging technology developer into a publicly traded medical device company listed on Nasdaq under the ticker NDRA. Its strategic positioning has focused on integrating its imaging platform with existing ultrasound systems rather than requiring entirely new imaging infrastructure.